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Chronic granulomatous disease is the manifestation
of genetic defects of the leukocyte NADPH oxidase
resulting in the absence of a respiratory burst.
Patients with chronic granulomatous disease can
develop chronic granulomas in many locations of the
body, including the skin. Using an established
murine model of X-linked chronic granulomatous
disease (X-CGD) created by homologous recombin-
ant disruption of the gene encoding the gp91phox
component of the NADPH oxidase, in this study we
examined cutaneous reactivity to sterile Aspergillus
fumigatus hyphae. Injection of Aspergillus fumigatus
into the dorsal ears of X-CGD mice resulted in an
enhanced in¯ammatory response by 24 h, consisting
of neutrophils, which developed into suppurative
granulomas by 10 d. Intradermal injection of
Aspergillus fumigatus into wild-type mice only resulted
in a transient in¯ammatory response that resolved by
10 d. Injection of Aspergillus fumigatus into female
carrier mice resulted in an acute in¯ammatory
response that was similar to that of wild-type mice,
but, at higher doses of Aspergillus fumigatus, many
carriers subsequently developed granulomatous
lesions that were qualitatively similar but smaller
than those seen in X-CGD mice by 30 d. Consistent
with the ability of X-CGD mice to mount an
enhanced neutrophil-rich in¯ammatory response to
Aspergillus fumigatus, signi®cant levels of the potent
neutrophil activator/chemoattractant leukotriene B4
were measured by mass spectrometry in skin biopsies
at 24 and 72 h. In contrast to the exaggerated in¯am-
matory response to intradermal Aspergillus fumigatus
in X-CGD mice compared to their wild-type
counterparts, similar levels of in¯ammation were
seen in a model of delayed-type hypersensitivity
using 2,4-dinitro¯uorobenzene. This study represents
the ®rst report of a cutaneous granuloma model in
mice with X-CGD, which may also prove useful as a
functional test to evaluate the ef®cacy of gene
therapy protocols being developed for chronic
granulomatous disease. Key words: chronic granuloma-
tous disease/leukotriene B4/NADPH oxidase/skin. J
Invest Dermatol 118:424±429, 2002
C
hronic granulomatous disease (CGD) is a rare genetic
disorder resulting from a nonfunctional leukocyte
NADPH oxidase enzyme complex (also referred to as
respiratory burst oxidase) estimated to affect 1 in
every 250,000 individuals (Dinauer, 1998; Segal et al,
2000). Because this superoxide-generating enzyme is essential for
the microbicidal activity of phagocytes (neutrophils, eosinophils,
and monocytes/macrophages), patients with CGD often suffer
from recurrent and even life-threatening bacterial and fungal
infections. Clinical manifestations include suppurative or granulo-
matous infections involving many organ systems, including the
skin. Other presentations, however, including eosinophilic pneu-
monia and skin lesions of discoid lupus erythematosus, tumid lupus
erythematosus, and atypical SweetõÂs syndrome have been seen in
patients with CGD (Rupec et al, 2000). Chronic granulomatous
disease can result from mutations in any one of four genes encoding
different subunits of the NADPH oxidase. The most common form
results from X-linked recessive mutations in the CYBB gene
located at Xp21.1, which encodes the gp91phox component of
NADPH oxidase. As a result of these gene defects, phagocytes are
unable to undergo a respiratory burst, thereby rendering them
unable to effectively eliminate catalase-positive bacterial and fungal
pathogens.
The active NADPH oxidase complex produces large quantities
of superoxide, which facilitates the killing of bacteria and fungi.
Activation of the NADPH oxidase requires the translocation of the
cytosolic components p47phox, p67phox, and the low molecular
weight GTPase Rac to the membrane-bound ¯avocytochrome
b588, which comprises two subunits, gp91phox and p22phox. The
assembled enzyme complex then transfers electrons from the
cytosolic NADPH to extracellular O2 generating superoxide anions
(Dinauer, 1998; Segal et al, 2000).
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Gene targeting has been used to develop mouse models for both
X-linked (gp91phox±/) and an autosomal recessive (p47phox±/±) form
of CGD (Jackson et al, 1995; Pollock et al, 1995). As is the case with
patients with CGD, neutrophils and macrophages in murine
models of CGD are unable to generate superoxide. CGD mice
exhibit increased susceptibility to infection with Staphylococcus
aureus and Pseudomonas cepacia, two pathogens that are often
problematic in patients (Pollock et al, 1995; Mardiney et al, 1997).
In addition, CGD mice are very sensitive to respiratory infection
with the opportunistic fungus Aspergillus fumigatus (AF). CGD mice
also have exaggerated in¯ammatory responses to intraperitoneal
instillation of thioglycolate or killed AF (Morgenstern et al, 1997).
Instillation of killed AF into the lung results in a chronic
pneumonitis with neutrophil-rich granulomatous lesions. Thus,
these mice have signi®cant abnormalities in both host defense and
in¯ammation that are similar to those in their human counterparts,
con®rming the importance of the respiratory burst in innate
immunity. Because skin granuloma formation is commonly seen in
CGD (Segal et al, 2000), the objective of this study was to assess the
ability of intradermal AF to induce in¯ammatory reactions in CGD
mice. Using gp91phox±/ mice, we demonstrate that intradermal
injection of sterile AF results in an intense, neutrophilic response
that then becomes granulomatous by 10 d, ®ndings that were not
seen in wild-type mice. Carrier mice exhibited a minimal early
response to AF, which was similar to that seen in wild-type mice.
Many carrier mice developed persistent granulomatous reactions by
30 d, however. Signi®cant levels of the potent neutrophil
activator/chemoattractant leukotriene B4 (LTB4) were found in
the early cutaneous reactions in CGD mice, suggesting possible
involvement of this eicosanoid in this process. These studies
provide a novel model system to study the role of the leukocyte
NADPH oxidase system in cutaneous in¯ammation, and provide a
potential marker for gene therapy studies.
MATERIALS AND METHODS
Reagents Routine chemicals were obtained from Sigma. LTB4 and
[6,7,14,15-d4]LTB4 were obtained from Cayman Chemical (Ann Arbor,
MI). All solvents were HPLC grade obtained from Fisher Scienti®c (Fair
Lawn, NJ).
Mice and skin in¯ammation protocols Two- to 5-mo-old C57/BL6
wild-type (WT), X-CGD (gp91phox±/), or carrier female (gp91phox±/+)
mice had been generated as described previously (Pollock et al, 1995)
and were housed under aseptic conditions. AP hyphae were harvested
and autoclaved, and hyphae were broken by sonication as previously
described (Morgenstern et al, 1997). The sterility of both AF and
phosphate-buffered saline (PBS) vehicle were assessed by lack of growth
by 3 d at 37°C following plating on both standard and Sabouraud's
dextrose agar. For intradermal injections, the mice were anesthetized
with intraperitoneal Avertin (2.5% vol/vol in 0.9% NaCl, 0.015±
0.025 ml per g body weight) and the dorsal aspects of one of the two
ears was injected with 50 ml of a solution containing 1±25 mg of AF,
with the contralateral ear injected with 50 ml of PBS vehicle. The mice
were then sacri®ced by CO2 asphyxiation at 1, 3, 10, and 30 d. A ®ve-
millimeter punch biopsy was then taken of each ear. Each biopsy was
weighed, measured for thickness with spring-loaded calipers (Mitutoyo),
®xed in formalin, and processed for histologic evaluation. Contact
hypersensitivity to 2,4-dinitro¯uorobenzene (DNFB) was assessed by
treatment of shaved back skin with 50 ml of 0.1% DNFB (2:1
acetone:olive oil). After 10 d, the dorsal ears were treated with 20 ml of
DNFB or vehicle. In¯ammation was assessed as above in 5 mm punch
biopsies 24 h following the elicitation phase.
LTB4 measurement In some ear punch biopsy specimens, LTB4 was
assessed following weighing of the tissues. Quantitation of LTB4 was
performed using a liquid chromatography/mass spectrometry (LC/MS/
MS) method that permitted quantitation in the low picogram per
milliliter concentration range with several modi®cations (Wheelan and
Murphy, 1997; Fiedler et al, 1998). Brie¯y, the tissue was frozen in
liquid nitrogen and crushed in a chilled glass homogenizer in 0.5 ml of
methanol (MeOH) with 500 pg of isotopically labeled deuterated d4-
LTB4 to serve as an internal standard. The homogenizer was washed
with 2 3 1 ml MeOH/H2O (1:1). Following centrifugation, the
supernatant was pulled into a syringe with 5 ml H2O. This solution was
then loaded into an SPE column (100 mg, C18 Varian Bond Elute)
prewashed with 2 ml MeOH followed by 4 ml H2O. The column was
then washed with 2 ml of H20, and the eicosanoid was eluted with 2 ml
of MeOH. Following drying, the samples were resuspended in 30 ml
MeOH and 60 ml mobile phase A (0.05% acetic acid, pH = 5.4). LC/
MS/MS was performed on Sciex API 3000 with Perkin Elmer Series
200 LC system. The column was a Phenomenex Columbus 5 m C18
1 3 150 mm with a gradient from 35% to 95% B (acetonitrile:MeOH
65:35) over 16 min, then isocratic at 95% B for 15 min. The mass
spectrometer was operated in the negative ion MRM mode. The
transition of the molecular anion to its major fragment was monitored
for each compound. For LTB4 the transition was m/z 335±195, for d4
LTB4 m/z 339±197. Peak areas and calibration curves were obtained
using the Sciex MacQuan program.
Statistical analysis Data from ear weight and thickness were analyzed
using one-way analysis of variance (ANOVA), and signi®cance was set at
p < 0.05.
RESULTS
Intradermal injection of AF induces in¯ammation The ®rst
studies assessed the cutaneous reactivity of wild-type C57Bl6,
X-CGD, or carrier mice to intradermal injections of 25 mg of
sterile AF. The dorsal ears of anesthetized mice were injected with
AF and PBS as control. As shown in Fig 1(A), AF-injected ears of
wild-type mice showed minimal clinical signs of in¯ammation. The
ears of X-CGD mice injected with AF were red and swollen by
24 h, however, with maximal visible in¯ammation by 72 h
(Fig 1B). The visible in¯ammatory response in carrier females was
similar to that in wild-type mice. Over time, a ®rm dermal papule
formed at the injection site in X-CGD mice, which lasted for at
least 4 wk. In many of the mice, the area ulcerated and healed with
a scar.
In¯ammation was quantitated at 1, 3, 10, and 30 d following
injection by measuring the weight and thickness of 5 mm punch
biopsies of PBS- and AF-injected ears as described in Methods. As
shown in Fig 2(A), injection of AF resulted in increased ear weight
over PBS-treated ears at day 1 in all three genotypes, with X-CGD
mice exhibiting the greatest increase. Unlike wild-type mice whose
ear weights normalized by 10 d postinjection, AF-treated X-CGD
mice exhibited substantial and statistically signi®cant increased ear
weight at all later time points examined. Of note, many (nine of 13)
female carrier mice exhibited late (30 d) in¯ammatory responses, as
manifested by increased weight (p < 0.05 compared to wild-type)
and thickness of biopsies, although these were not as pronounced as
X-CGD mice. Measurement of ear thickness of the skin biopsies
mirrored the ear weights, as shown in Fig 2(B).
The next studies examined whether lower doses of AF could
induce aberrant in¯ammatory responses in X-CGD mice. As
shown in Fig 3, intradermal injection of even 1 mg of AF resulted
in signi®cant in¯ammation in X-CGD mice that persisted for at
least 30 d following injection. Ear thickness measurements mir-
rored the ear weights (data not shown). Measurement of ear
thickness and weights in female carrier mice (n = 6 animals)
injected with 2.5 mg AF showed no enhanced in¯ammatory
response compared to wild-type mice, although larger doses
(25 mg) of AF could induce an in¯ammatory response in some
carrier mice at 30 d (Fig 2).
Histologic analysis of AF skin reactions Punch biopsy
specimens from all animals were ®xed in formalin, routinely
processed, stained with hematoxylin and eosin and examined
microscopically in blinded fashion by a dermatopathologist. As
shown in Fig 1, for all animals, biopsy specimens taken 24 h after
injection of 25 mg AF demonstrated dermal neutrophilic in®ltrates,
although these were most pronounced in X-CGD mice. By day 3,
however, essentially no in¯ammatory in®ltrates were seen in ear
specimens from all wild-type and from many carrier mice. In
contrast, specimens from X-CGD mice demonstrated dense
in®ltrates consisting predominantly of neutrophils on day 1 and
day 3 after AF injection. By day 10, an acute and chronic
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in¯ammatory reaction consisting of neutrophils, mononuclear cells,
and giant cells (suppurative and granulomatous response) was seen
in X-CGD mice (Fig 1G). Biopsies taken from AF-treated
X-CGD mice on day 30 showed epithelioid histiocytic cells
admixed with neutrophils in a ®brotic stroma (Fig 1H, I). Neither
wild-type nor carrier mice injected with a smaller amount (2.5 mg)
of AF exhibited any abnormal histologic changes at 30 d.
Histologic changes similar to those seen in X-CGD, however,
though quantitatively diminished, were seen in nine of 13 of the
carriers 30 d after injecting larger amounts (25 mg) of AF.
Figure 1. Clinical and histologic analysis of AF-induced skin reactions. Sterile AF (25 mg) and PBS vehicle were injected into the dorsal ears of
wild-type, carrier, or X-CGD mice. At various times, the animals were sacri®ced and 5 mm punch biopsies from the ears were processed for histologic
evaluation. Gross photographs of (A) wild-type and (B) X-CGD mice 72 h following intradermal injection with PBS (left ear) and AF (right ear).
Hematoxylin and eosin stained sections from AF-injected (C) wild-type, (D) carrier, and (E) X-CGD mice 24 h after AF injection reveal
predominantly neurophilic in®ltrates. (F) Dense neutrophil-rich in®ltrates were seen in X-CGD mice 3 d after AF injection. (G) Suppurative and
granulomatous response in X-CGD mice 10 d after AF injection. (H) Epithelioid granulomas admixed with neutrophils in a ®brotic stroma in X-CGD
mice 30 d after AF injection. Scale bar: 1250 mm. (I) Higher magni®cation of reaction in X-CGD mice at 30 d. Scale bar: 100 mm.
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Delayed-type hypersensitivity responses in X-CGD
mice The ®ndings that AF-induced cutaneous responses were
exaggerated in X-CGD mice led to further studies to de®ne
whether other types of in¯ammatory responses were also abnormal
in these mice. Delayed-type hypersensitivity reactions were chosen
as this type of in¯ammatory response primarily involves T cells and
macrophages, not neutrophils. Wild-type and X-CGD mice were
sensitized with DNFB, and then either DNFB or vehicle was
applied to dorsal ears as described in Methods. In¯ammation was
again assessed in 5 mm punch biopsy specimens by measurement of
tissue weight and thickness 1 d following challenge with DNFB.
The differences in ear weights in this model of contact
hypersensitivity were similar in nine wild-type (7.4 6 2.1 mg)
and X-CGD (8.1 6 0.9 mg) mice. Measurements of ear thickness
also were not different between the two types of mice (data not
shown). These studies suggest that X-CGD mice have normal
delayed-type hypersensitivity reactions.
Measurement of LTB4 in AF-induced cutaneous
in¯ammation LTB4 is a potent neutrophil activator and
chemoattractant (Williams et al, 1988). Inasmuch as neutrophils
constituted the major cell type at days 1 and 3 in AF-induced
cutaneous in¯ammatory response in X-CGD mice (Fig 1), and
previous studies suggest that CGD neutrophils produce more LTB4
than their normal counterparts (Hamasaki et al, 1989), the next
studies used a sensitive and speci®c liquid chromatography mass
spectrometric protocol to measure LTB4 accumulation in vivo in
response to AF in wild-type versus X-CGD mice. Table I
compares ear weight and LTB4 levels in 5 mm punch biopsies in
PBS- versus AF-injected ears at days 1 and 3. As shown in Table I,
signi®cantly greater (p < 0.01) levels of LTB4 were seen in AF-
treated X-CGD versus wild-type mice. Given that the KD of the
LTB4 receptor is in the high picomolar to low nanomolar range
(Yokomizo et al, 1997), the amounts of LTB4 measured in X-CGD
mice in response to AF are physiologically relevant, and similar to
other model systems of LTB4 production including that induced by
topical arachidonic acid (Tsuji et al, 1998; Romay et al, 1999).
DISCUSSION
These studies demonstrate that intradermal injection of sterile AF
hyphae results in aberrant hyperactive cutaneous in¯ammatory
reactions in mice that lack a functional leukocyte NADPH oxidase.
Exposure to AF resulted in a neutrophil-rich in¯ammatory
response, which became more granulomatous over time. These
®ndings are consistent with granulomatous responses seen in
X-CGD mice following lung exposure to AF (Morgenstern et al,
1997). In addition, similar lung and cutaneous granulomas are
found in the human chronic granulomatous disease (Gallin et al,
1983; Segal et al, 2000).
Challenge with AF resulted in an exaggerated early response
consisting of neutrophils in X-CGD mice, with only minimal acute
in¯ammatory changes in wild-type or carrier mice. Many (nine of
Figure 3. Effects of various doses of intradermal AF on ear
biopsy weight in X-CGD mice. Sterile AF (1, 2.5, 5, or 25 mg) and
PBS vehicle were injected into the dorsal ears of X-CGD mice. At 30 d,
the animals were sacri®ced and the weights of 5 mm punch biopsies
from the ears were assessed as described in Fig 2. The data are the mean
6 SD difference in tissue weight between AF- and PBS-treated ears.
The numbers in parentheses denote the number of animals tested at each
time point.
Figure 2. Effects of intradermal AF on ear biopsy weight and
thickness. Sterile AF (25 mg) and PBS vehicle were injected into the
dorsal ears of wild-type, carrier, or X-CGD mice. At various times, the
animals were sacri®ced and 5 mm punch biopsies from the ears were (A)
weighed, and (B) the thickness was determined with spring-loaded
calipers. The data are the mean 6 SD difference in tissue weight or
percentage increase between AF- and PBS-treated ears. The numbers in
parentheses denote the number of animals tested at each time point (and
are the same for parts A and B). The differences between AF-treated
X-CGD were statistically signi®cant (ANOVA; p < 0.001) over wild-
type mice at all time points tested, and carrier mice at days 1, 3, and 10.
The differences between ear thickness and weights were statistically
signi®cant in X-CGD mice over carrier mice at 30 d (p < 0.05).
Differences between ear thickness and weights between carrier and wild-
type mice did not reach statistical signi®cance at days 1, 3, and 10, but
ear weights (but not thickness) were statistically signi®cant (p < 0.05) at
day 30.
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13) carrier mice, however, exhibited late granulomatous reactions
in response to 25 mg of AF at 30 d. This chronic in¯ammatory
response was dose dependent in that none of the carrier mice (none
of six) injected with 2.5 mg of AF exhibited granulomas at 30 d.
These ®ndings contrast with the mild and self-limited in¯ammation
induced by even 25 mg of AF in wild-type mice. These ®ndings
suggest that lacking even half the normal numbers of NADPH-
oxidase-positive neutrophils could have potential clinical manifest-
ations. Indeed, the abnormal phenotype found in carrier mice ®ts
with reports of a spectrum of cutaneous in¯ammatory lesions
described in human CGD carriers (Schaller, 1972; Rupec et al,
2000).
The enhanced response to AF injection in X-CGD mice
appeared to be rather speci®c, as wild-type and X-CGD mice
reacted similarly in a mouse model system of delayed contact
hypersensitivity. In addition, topical treatment with 1 mg of the
protein kinase C activator tetradecanoyl phorbol acetate resulted in
similar levels of in¯ammation at 24 h as assessed by punch biopsy
ear weights and thickness in four wild-type and X-CGD mice (data
not shown).
The mechanism by which lack of a neutrophil respiratory burst
results in an exaggerated cutaneous response to killed AF hyphae is
not clear. Preliminary data from our laboratory suggest that
oxidants produced by the neutrophil are important in the
breakdown of the AF hyphae (Hiran and Dinauer, manuscript in
preparation). The inability to digest and remove this foreign
material could then result in a granulomatous response. Indeed,
granuloma formation is a common cutaneous response to
undigestible foreign material including silica or even keratin from
ruptured epidermal cysts (White, 2000). This hypothesis would
explain the late granulomatous response but not the early increased
neutrophil-rich in¯ammatory response seen by 24 h in X-CGD
mice, however.
Potential explanations for the enhanced early in¯ammatory
response in X-CGD mice could include increased in¯ammatory
mediator production, and/or increased survival of exudate
neutrophils. Recent studies suggest that the life of a neutrophil in
tissue is measured in hours, and that activation of the respiratory
burst is a potent signal for this cell to undergo apoptosis (Hiraoka
et al, 1998; Lundqvist-Gustafsson and Bengtsson, 1999). Recent
data that suggest that neutrophils derived from X-CGD mice
appear to be protected from apoptosis compared with those from
wild-type mice ®t with this notion that the prolonged survival of
NADPH-oxidase-negative neutrophils might play a role in the
increased early in¯ammatory response.
A second explanation for the enhanced early in¯ammatory
response could be the increased generation (or lack of metabolism)
of neutrophil activators and chemoattractants. LTB4 is a potent
neutrophil-speci®c activator and chemoattractant that could be one
of many possible mediators involved in the enhanced early response
seen in X-CGD mice. Topical application of LTB4 in human
volunteers has been reported to result in neutrophil-rich epidermal
and dermal pustules (Camp et al, 1984). Of note, neutrophils from
patients with CGD have been reported to produce increased
amounts of LTB4 in vitro (Henderson and Klebanoff, 1983;
Hamasaki et al, 1989). Recent studies suggest involvement of
5-lipoxygenase products, as systemic treatment with the 5-
lipoxygenase inhibitor zileuton inhibits the early increased
neutrophil response to intraperitoneal AF (Hiran and Dinauer,
manuscript in preparation). This study demonstrating signi®cant
levels of LTB4 accumulation in AF-treated ears in X-CGD mice
(Table I) also ®ts with potential involvement of this eicosanoid in
the early in¯ammatory response. Future studies will examine the
roles of potential decreased neutrophil apoptosis and the enhanced
production of in¯ammatory mediators such as LTB4 in the aberrant
cutaneous responsiveness of X-CGD mice to intradermal AF.
Finally, other important effectors of the innate immune system
such as complement could also be involved in the hyper-
responsiveness of X-CGD mice to killed AF. The complement
cascade is an important mechanism for microbial clearance. The
lack of AF degradation would be expected to enhance complement
activation, with resultant overproduction of anaphylotoxins.
This work has established a novel murine model system for
cutaneous granulomas in the X-CGD mouse. Using clinical,
histologic, and physical measurements this study demonstrates that
the X-CGD mouse develops a persistent in¯ammatory response
following intradermal injection of sterilized AF. In addition to
developing a model system to study the role of the NADPH
oxidase response in cutaneous in¯ammation, these studies have
clinical implications. Currently, the mainstay of therapy for CGD is
prophylactic antibiotics and gamma interferon (Segal et al, 2000).
CGD is a candidate disease for gene therapy targeted at
hematopoietic stem cells (reviewed by Kume and Dinauer,
2000), however. Inasmuch as superoxide production in only
»10%±20% of neutrophils may be suf®cient to protect X-CGD
heterozygotes from most serious infections, complete ablation of
endogenous bone marrow may not be required in the disease
(Roos et al, 1996; Bjorgvinsdottir et al, 1997; Dinauer et al, 1999).
Previous in vitro studies have demonstrated the utility of retroviral
vectors to transduce human X-CGD cells to restore high level
oxidase activity (Becker et al, 1998) and gene-corrected neutrophils
can be detected for at least 18±24 mo in the murine X-CGD model
(Dinauer et al, 1999). Correction of neutrophil NADPH oxidase
activity by retroviral-mediated gene transfer has also been shown to
rescue the host against AF and P. cepacia (Bjorgvinsdottier et al,
1997; Dinauer et al, 1999). The cutaneous in¯ammation induced
by AF will be a useful model to evaluate the impact of further gene
therapy on the chronic in¯ammatory manifestations of CGD.
Finally, this murine system presents a new opportunity to study
cutaneous granuloma formation. Granulomatous diseases in derma-
tology, such as sarcoidosis, necrobiosis lipoidica, and granuloma
annulare, are not well understood and their treatment can be
challenging. Currently there are few animal models for studying
granulomatous diseases and their treatment modalities. Our model
presents the chance to further study, understand, and potentially
design new treatments for these disease processes.
These studies were supported in part by grants from the Showalter Memorial
Foundation, the Riley Memorial Association, and National Institutes of Health
grants K08AR1993, HL62996, HL52565, HL53586, and HL34303.
Table I. Ear punch biopsy weight and LTB4 measurement
in wild-type and X-CGD mice following injection with AF
or PBSa
Mouse type/
time
PBS ear
weight
(mg)
PBS LTB4
(pg)
AF ear
weight
(mg)
AF LTB4
(pg)
WT 24 h 5.6 3.2 6.5 10.4
WT 24 h 6.3 0.7 7.0 19.6
WT 72 h 5.6 7 5.8 4.5
WT 72 h 5.9 5.4 6.1 7.8
X-CGD 24 h 4.8 10.4 10.4 224
X-CGD 24 h 4.0 9.5 6.6 58.5
X-CGD 24 h 4.8 5.7 8.7 174
X-CGD 24 h 4.5 14.8 7.5 327
X-CGD 72 h 4.8 3.0 10.2 150
X-CGD 72 h 5.2 12.7 16.5 215
X-CGD 72 h 5.0 3.3 13.7 178
X-CGD 72 h 5.4 5.0 12.6 135
aSterile AF (25 mg) and PBS vehicle were injected into the dorsal ears of wild-
type or X-CGD mice. At either 24 h or 72 h, the animals were sacri®ced, 5 mm
punch biopsies from the ears were weighed, and LTB4 were levels measured.
ANOVA test indicated that LTB4 levels in AF-treated X-CGD were statistically
signi®cant (p < 0.01) over both PBS-treated X-CGD as well as AF-treated wild-
type mice.
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